© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Thomas J. Lynch, MD, discusses the treatment of patients with T790M-mutant non-small cell lung cancer (NSCLC).
Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses the treatment of patients withT790M